Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Venous thromboembolism: implications for gene-based diagnosis and technology development.

W Craig Hooper1, Christine De Staercke

  • 1Hematologic Disease Branch, Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA 30333, USA. chooper@cdc.gov

Expert Review of Molecular Diagnostics
|December 6, 2002
PubMed
Summary

Venous thromboembolism (VTE) risk is influenced by genetics, including the common FV Leiden mutation. This discovery accelerated the development of DNA analysis technologies for VTE research and clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between thromboembolic events and COVID-19 infection within 30 days: a case-control study among a large sample of adult hospitalized patients in the United States, March 2020-June 2021.

Journal of thrombosis and thrombolysis·2022
Same author

Vital Signs: Use of Recommended Health Care Measures to Prevent Selected Complications of Sickle Cell Anemia in Children and Adolescents - Selected U.S. States, 2019.

MMWR. Morbidity and mortality weekly report·2022
Same author

Prioritizing Sickle Cell Disease.

Pediatrics·2022
Same author

COVID-19 and Sickle Cell Disease-Related Deaths Reported in the United States.

Public health reports (Washington, D.C. : 1974)·2022
Same author

Trends in Sickle Cell Disease-Related Mortality in the United States, 1979 to 2017.

Annals of emergency medicine·2020
Same author

Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)·2020

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Hematology

Background:

  • Venous thromboembolism (VTE) is a hypercoagulable state influenced by inherited, acquired, and environmental factors.
  • VTE incidence increases with age, affecting approximately 1 in 1000 individuals in Western countries.
  • Genetic variants, such as FV Leiden, are significant risk factors for VTE, particularly in idiopathic cases.

Purpose of the Study:

  • To review the technology and its relationship to the genetics of venous thromboembolism.
  • To highlight the impact of FV Leiden discovery on VTE research and diagnostics.

Main Methods:

  • Review of existing literature on VTE genetics and mutation detection technologies.
  • Analysis of the prevalence and impact of the FV Leiden mutation.

Related Experiment Videos

Main Results:

  • The FV Leiden mutation, a common single nucleotide polymorphism, is found in about 20% of idiopathic VTE cases.
  • The discovery of FV Leiden spurred interest in cardiovascular disease genetics and advanced DNA analysis platforms.
  • Novel mutation detection methodologies have been developed for clinical and research applications.

Conclusions:

  • Genetic factors play a crucial role in the pathogenesis of venous thromboembolism.
  • The FV Leiden mutation serves as a key example of genetic influence on VTE risk.
  • Technological advancements in DNA analysis are essential for understanding and managing VTE.